Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 28;84(5):1681-1706.
doi: 10.1021/acs.jnatprod.1c00100. Epub 2021 May 11.

Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors

Affiliations
Review

Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors

Arun K Ghosh et al. J Nat Prod. .

Abstract

Spliceostatins and thailanstatins are intriguing natural products due to their structural features as well as their biological significance. This family of natural products has been the subject of immense synthetic interest because they exhibit very potent cytotoxicity in representative human cancer cell lines. The cytotoxic properties of these natural products are related to their ability to inhibit spliceosomes. FR901564 and spliceostatins have been shown to inhibit spliceosomes by binding to their SF3B component. Structurally, these natural products contain two highly functionalized tetrahydropyran rings with multiple stereogenic centers joined by a diene moiety and an acyclic side chain linked with an amide bond. Total syntheses of this family of natural products led to the development of useful synthetic strategies, which enabled the synthesis of potent derivatives. The spliceosome modulating properties of spliceostatins and synthetic derivatives opened the door for understanding the underlying spliceosome mechanism as well as the development of new therapies based upon small-molecule splicing modulators. This review outlines the total synthesis of spliceostatins, synthetic studies of structural derivatives, and their bioactivity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1.
Figure 1.
Thailanstatin A SAR.
Scheme 1.
Scheme 1.
FR901464 Retrosynthesis
Scheme 2.
Scheme 2.
Synthesis of Vinyl Iodide 14
Scheme 3.
Scheme 3.
Synthesis of Vinyl Iodide 15
Scheme 4.
Scheme 4.
Synthesis of Carboxylic Acid 16
Scheme 5.
Scheme 5.
Jacobsen Synthesis of FR901464
Scheme 6.
Scheme 6.
FR901464 Retrosynthesis by Kitahara and Co-workers
Scheme 7.
Scheme 7.
Synthesis of Sulfone 49
Scheme 8.
Scheme 8.
Synthesis of Aldehyde 55
Scheme 9.
Scheme 9.
Synthesis of Carboxylic Acid 42
Scheme 10.
Scheme 10.
Kitahara Synthesis of FR901464
Scheme 11.
Scheme 11.
Synthetic Strategy for FR901464
Scheme 12.
Scheme 12.
Synthesis of Functionalized Tetrahydropyran 64
Scheme 13.
Scheme 13.
Synthesis of Tosyl Derivative 79
Scheme 14.
Scheme 14.
Koide Synthesis of 16
Scheme 15.
Scheme 15.
Koide Synthesis of FR901464
Scheme 16.
Scheme 16.
Synthesis of C-1-Dimethyl Analogue of FR901464
Scheme 17.
Scheme 17.
Synthesis of Meayamycin B (96)
Scheme 18.
Scheme 18.
Synthetic Strategy for FR901464 and Spliceostatin A
Scheme 19.
Scheme 19.
Synthesis of Tetrahydropyran Ring A 97
Scheme 20.
Scheme 20.
Synthesis of Z-Allylic Acetate 16
Scheme 21.
Scheme 21.
Synthesis of Tetrahydropyran Ring B 65
Scheme 22.
Scheme 22.
Synthesis of Spliceostatin A and FR901464
Scheme 23.
Scheme 23.
Synthetic Strategy for the C-1-Cyclopropane Derivative (122) of FR901464 (1)
Scheme 24.
Scheme 24.
Syntheses of Ring A Alkene 123 and Vinyl Iodide 124 Derivatives
Scheme 25.
Scheme 25.
Synthesis of Vinyl Boronate 125
Scheme 26.
Scheme 26.
Synthesis of C-1-Cyclopropane Derivative 122 via Cross-Metathesis
Scheme 27.
Scheme 27.
Synthesis of C-1-Cyclopropane Derivative 122 via Suzuki coupling
Scheme 28.
Scheme 28.
Synthesis of Spliceostatin G
Scheme 29.
Scheme 29.
Synthetic Strategy for Spliceostatin E
Scheme 30.
Scheme 30.
Synthesis of Dihydropyranone 142
Scheme 31.
Scheme 31.
Synthesis of Z-Allylic Acetate 16
Scheme 32.
Scheme 32.
Synthesis of Spliceostatin E
Scheme 33.
Scheme 33.
Synthetic Strategy for Thailanstatin A
Scheme 34.
Scheme 34.
Enantioselective Synthesis of 65 from Tri-O-acetyl-d-glucal
Scheme 35.
Scheme 35.
Synthesis of Epoxy Olefin Derivative 151
Scheme 36.
Scheme 36.
Final Coupling to Form Thailanstatin A Methyl Ester
Scheme 37.
Scheme 37.
Nicolaou’s Synthetic Strategy for Thailanstatin A
Scheme 38.
Scheme 38.
Synthesis of Vinyl Iodides 169 and 170
Scheme 39.
Scheme 39.
Nicolaou’s Synthesis of Z-Allylic Acetate 16
Scheme 40.
Scheme 40.
Synthesis of Dihydropyran Derivative 178
Scheme 41.
Scheme 41.
Optimized Synthesis of Vinyl Boronate 125
Scheme 42.
Scheme 42.
Syntheses of Spliceostatin D, Thailanstatin A, and Thailanstatin B
Scheme 43.
Scheme 43.
Synthesis of Thailanstatin C
Scheme 44.
Scheme 44.
Boger Meayamycin A (90) Retrosynthesis
Scheme 45.
Scheme 45.
Boger Synthesis of Tetrahydropyran Ring A
Scheme 46.
Scheme 46.
Boger Synthesis of Tetrahydropyran Ring B
Scheme 47.
Scheme 47.
Synthesis of O-Acyl Meayamycin Derivatives

Similar articles

Cited by

References

    1. Newman DJ; Cragg GW Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019 J. Nat. Prod 2020, 83, 770–803. - PubMed
    1. Newman DJ; Cragg GM J. Nat. Prod 2007, 70 (3), 461–477. - PubMed
    1. Haustedt LO; Mang C; Siems K; Schiewe H Curr. Opin. Drug Discovery Dev 2006, 9 (4), 445–462. - PubMed
    1. Koch MA; Schuffenhauer A; Scheck M; Wetzel S; Casaulta M; Odermatt A; Ertl P; Waldmann H Proc. Natl. Acad. Sci. U. S. A 2005, 102 (48), 17272–17277. - PMC - PubMed
    1. Maier ME Org. Biomol. Chem 2015, 13 (19), 5302–5343. - PubMed

Publication types

MeSH terms